findmyKOL

Holly Middlekauff, MD

Enriched profile

Professor of Medicine, David Geffen School of Medicine at UCLA; Cardiologist, UCLA Health · UCLA Health

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Los Angeles, CA · West · United StatesSpecialtyCardiovascular DiseaseFocusHeart Rate Variability and Autonomic Control+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2023–2023NIH funding1995–2010

Holly Middlekauff is Professor of Medicine, David Geffen School of Medicine at UCLA; Cardiologist, UCLA Health at UCLA Health. OpenAlex indexes 204 publications with 10,027 citations (h-index 54); ClinicalTrials.gov lists 3 registered studies with this person as an investigator.

Data verified 11 Oct 2026

Overview

Updated 14 Oct 2026

Holly Middlekauff, MD, is Professor of Medicine, David Geffen School of Medicine at UCLA at UCLA Health. The public record shows 204 publications with 10,027 citations (h-index 54), centered on Heart Rate Variability and Autonomic Control, Cardiovascular and exercise physiology, Smoking Behavior and Cessation. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 1 companies, 5 NIH-funded awards (1995–2010).

  • Most recent indexed publication: 2026 · Circulation research
  • Top research focus: Heart Rate Variability and Autonomic Control
  • 3 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 1 companies

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Heart Failure2 trialsInflammation1 trialArteritis1 trial

Research focus

OpenAlex concept fingerprint
Heart Rate Variability and Autonomic ControlCardiovascular and exercise physiologySmoking Behavior and CessationHeart Failure Treatment and ManagementCardiac electrophysiology and arrhythmias

Works with

trial sponsors and companies reporting payments
University of California, Los AngelesClinical trials2Industry payments—Cook Medical LLCClinical trials—Industry payments1National Center for Complementary and Integrative Health (NCCIH)Clinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
204publications

Distinct works indexed by OpenAlex, matched via ORCID; 15 in PubMed.

10,027citations

Total citations across indexed works.

54h-index

Hirsch index (OpenAlex). i10-index 118.

Clinical & industry

trials, payments and federal funding
3clinical trials

Investigator role on registered studies.

View trials ↓
1companies · 2023–2023

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
5NIH grants · 1995–2010

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 14 Oct 2026

1 company reported payments to CMS in program years 2023–2023. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    80.7%
    Statin21.1%
    Atorvastatin Calcium66%Rosuvastatin Calcium29%Livalo3%Pravastatin Sodium3%
    Part D<11 patients
    Beta blocker15%
    Metoprolol Succinate44%Carvedilol27%Metoprolol Tartrate24%Atenolol4%
    Part D<11 patients

    + 14 more classes in this area

  • Blood & clotting

    11.4%
    Factor Xa inhibitor7.9%
    Eliquis78%Xarelto22%
    Part D<11 patients
    P2Y12 inhibitor3.5%
    Clopidogrel100%
    Part D≥17 patients
  • Metabolism & gastrointestinal

    7.8%
    SGLT2 inhibitor4.9%
    Farxiga52%Jardiance48%
    Part D≥13 patients
    Potassium supplement3%
    Potassium Chloride100%
    Part D≥16 patients
Where care is delivered (Part B)87.9% facility · 12.1% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 14 Oct 2026

5 NIH research awards on record, funded 1995–2010 per NIH RePORTER. The latest:

Publications

Updated 14 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 14 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Carlos Eduardo Negrão40JEFFREY A. GORNBEIN32William G. Stevenson30Maria Urbana Pinto Brandão Rondon29Gregg C. Fonarow24Antônio Carlos Pereira Barretto23Isabelle Ruedisueli21Leslie A. Saxon20Lynne Warner Stevenson19Michèle A. Hamilton19Elizabeth U. Tran17Theodoros Kelesidis16Roya S. Moheimani15Patrı́cia C. Brum15Jesús A. Araujo13Jeanie Park13Jaime D. Moriguchi13Karishma Lakhani12Lígia M. Antunes‐Correa11Antoine Hage10Kacey P. Haptonstall9Mary A. Woo9Ziva D. Cooper8Yasmine Choroomi8Thais S. Nobre8Fabiana Roveda8Kevin Nguyen8Tamara B. Horwich8Katherine E. Hampilos7Randy Nguyen7Sara Arastoo7Ana Braga7Marcelo Rodrigues dos Santos6Fen Yin6Maria Janieire de Nazaré Nunes Alves6Kacey M. Peters6Egbert U. Nitzsche6Linda Massako Ueno6Paul D. Natterson6Raphaela V. Groehs6

Online presence

Updated 14 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/holly-middlekauff-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board certified

    Cardiovascular Disease, American Board of Internal Medicine

    1993
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
  • Board certified

    Internal Medicine, American Board of Internal Medicine

    1989
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
  • MD

    Keck School of Medicine of USC

    1986
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.